On December 3, 2020 Victor Levitysky, Chief Scientific Officer of Targovax and primary insider, reported that purchased on 2 December 2020 10,000 shares in Targovax ASA ("the Company") at an average share price of NOK 10 per share (Press release, Targovax, DEC 3, 2020, View Source [SID1234572107]). Following this transaction, Victor Levitsky holds 10,000 shares and 250,000 share options in the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!